<!DOCTYPE html>
<html lang="en">
<head>
<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Research Q&A — Judicialização da Saúde</title>
<style>
  :root {
    --bg: #f8f9fa; --card: #fff; --fg: #1a1a1a; --muted: #666;
    --border: #dee2e6; --accent: #0d6efd; --accent2: #198754;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    background: var(--bg); color: var(--fg); line-height: 1.5;
  }

  main {
    padding: 1.5rem 2rem 3rem; max-width: 900px; margin: 0 auto;
  }

  /* Markdown body styles */
  .md-body { font-size: .92rem; line-height: 1.7; color: #1f2328; }

  .md-body h1 { font-size: 1.5rem; font-weight: 600; margin: 1.8rem 0 .8rem; padding-bottom: .3rem; border-bottom: 1px solid var(--border); }
  .md-body h2 { font-size: 1.25rem; font-weight: 600; margin: 1.6rem 0 .6rem; padding-bottom: .25rem; border-bottom: 1px solid var(--border); }
  .md-body h3 { font-size: 1.05rem; font-weight: 600; margin: 1.3rem 0 .5rem; }
  .md-body h4 { font-size: .95rem; font-weight: 600; margin: 1.1rem 0 .4rem; }
  .md-body h5, .md-body h6 { font-size: .88rem; font-weight: 600; margin: 1rem 0 .4rem; }
  .md-body h1:first-child { margin-top: 0; }

  .md-body p { margin: 0 0 .8rem; }

  .md-body ul, .md-body ol { margin: 0 0 .8rem; padding-left: 1.8rem; }
  .md-body li { margin-bottom: .25rem; }
  .md-body li > ul, .md-body li > ol { margin-top: .25rem; margin-bottom: 0; }

  /* Task lists */
  .md-body ul li { list-style: disc; }
  .md-body li input[type="checkbox"] {
    margin-right: .4rem; vertical-align: middle; position: relative; top: -1px;
  }

  .md-body a { color: var(--accent); text-decoration: none; }
  .md-body a:hover { text-decoration: underline; }

  .md-body strong { font-weight: 600; }

  .md-body blockquote {
    margin: 0 0 .8rem; padding: .4rem 1rem;
    border-left: 4px solid var(--accent); background: #f0f4f8;
    color: #555; font-size: .88rem;
  }
  .md-body blockquote p:last-child { margin-bottom: 0; }

  .md-body code {
    font-family: "SFMono-Regular", Consolas, "Liberation Mono", Menlo, monospace;
    font-size: .85em; background: #eef1f5; padding: .15rem .35rem;
    border-radius: 4px;
  }
  .md-body pre {
    margin: 0 0 .8rem; padding: .9rem 1rem;
    background: #f6f8fa; border: 1px solid var(--border);
    border-radius: 6px; overflow-x: auto; line-height: 1.45;
  }
  .md-body pre code {
    background: none; padding: 0; font-size: .82rem;
  }

  .md-body table {
    width: 100%; border-collapse: collapse; margin: 0 0 .8rem;
    font-size: .85rem; display: block; overflow-x: auto;
  }
  .md-body th, .md-body td {
    padding: .45rem .7rem; border: 1px solid var(--border); text-align: left;
  }
  .md-body th { background: #f0f4f8; font-weight: 600; }
  .md-body tr:nth-child(even) td { background: #fafbfc; }

  .md-body hr {
    border: none; border-top: 1px solid var(--border); margin: 1.5rem 0;
  }

  .md-body img { max-width: 100%; }

  /* Collapsible sections */
  .doc-controls { margin-bottom: 1rem; }
  .doc-controls button {
    font-size: .8rem; padding: .3rem .7rem; cursor: pointer;
    background: var(--card); border: 1px solid var(--border); border-radius: 4px;
    color: var(--accent); font-weight: 600;
  }
  .doc-controls button:hover { background: #e7f1ff; }
  .md-body details { margin-bottom: .5rem; }
  .md-body details summary {
    font-weight: 600; cursor: pointer; list-style: none;
  }
  .md-body details summary::-webkit-details-marker { display: none; }
  .md-body details summary::before {
    content: "\25b6"; font-size: .7em; margin-right: .5rem;
    display: inline-block; transition: transform .15s;
  }
  .md-body details[open] summary::before { transform: rotate(90deg); }
  .md-body details.level-2 > summary {
    font-size: 1.25rem; padding-bottom: .25rem;
    border-bottom: 1px solid var(--border); margin: 1.6rem 0 .6rem;
  }
  .md-body details.level-3 > summary {
    font-size: 1.05rem; margin: 1.3rem 0 .5rem;
  }

  footer {
    text-align: center; padding: 1.5rem; font-size: .8rem; color: var(--muted);
    border-top: 1px solid var(--border); margin-top: 2rem;
  }
</style>
</head>
<body>

<style>
  .site-nav {
    position: sticky; top: 0; z-index: 100;
    background: #212529; display: flex; align-items: center;
    padding: 0 2rem; height: 3rem;
  }
  .site-nav .nav-brand {
    color: #fff; text-decoration: none; font-weight: 600; font-size: 1rem;
    margin-right: auto;
  }
  .site-nav .nav-brand:hover { color: #e9ecef; }
  .site-nav .nav-link {
    color: #adb5bd; text-decoration: none; font-size: .85rem;
    padding: 0 .75rem; height: 3rem; display: flex; align-items: center;
    background: none; border: none; cursor: pointer; font-family: inherit;
  }
  .site-nav .nav-link:hover, .site-nav .nav-link.active { color: #fff; }
  .nav-dropdown { position: relative; }
  .dropdown-menu {
    display: none; position: absolute; top: 3rem; right: 0;
    background: #fff; border: 1px solid var(--border); border-radius: 6px;
    box-shadow: 0 4px 16px rgba(0,0,0,.12); min-width: 220px;
    padding: .4rem 0; z-index: 200; max-height: 80vh; overflow-y: auto;
  }
  .nav-dropdown.open .dropdown-menu { display: block; }
  .dropdown-menu a {
    display: block; padding: .3rem 1rem; color: #1a1a1a;
    text-decoration: none; font-size: .82rem;
  }
  .dropdown-menu a:hover { background: #f0f4f8; }
  .dropdown-group-label {
    padding: .4rem 1rem .15rem; font-size: .68rem; font-weight: 700;
    color: #888; text-transform: uppercase; letter-spacing: .04em;
  }
  .dropdown-divider { border-top: 1px solid #eee; margin: .3rem 0; }
  .page-header {
    padding: .8rem 2rem; border-bottom: 1px solid var(--border); background: #fff;
  }
  .page-header h1 { font-size: 1.3rem; font-weight: 600; }
  .page-header p { color: var(--muted); font-size: .85rem; margin-top: .15rem; }
</style>

<nav class="site-nav">
  <a href="../index.html" class="nav-brand">Judicialização da Saúde</a>
  <a href="../paper/index.html" class="nav-link">Paper</a>
  <div class="nav-dropdown">
    <button class="nav-link active">Docs &#9662;</button>
    <div class="dropdown-menu">
    <div class="dropdown-group-label">Research reference</div>
    <a href="../docs/README.html">Project Overview</a>
    <a href="../docs/summary.html">Research Summary</a>
    <a href="../docs/institutions.html">Institutional Background</a>
    <a href="../docs/data.html">Data Sources</a>
    <a href="../docs/methods.html">Empirical Methods</a>
    <a href="../docs/literature.html">Literature</a>
    <a href="../docs/theory.html">Theoretical Framework</a>
    <a href="../docs/hypotheses.html">Hypotheses & Evidence</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Working notes</div>
    <a href="../docs/thinking.html">Open Questions & Ideas</a>
    <a href="../docs/decisions.html">Key Decisions</a>
    <a href="../docs/qa.html">Research Q&A</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Task tracking</div>
    <a href="../docs/todo.html">Active Tasks</a>
    <a href="../docs/done.html">Completed Tasks</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Communication</div>
    <a href="../docs/meetings.html">Meeting Notes</a>
    <a href="../docs/feedback.html">External Feedback</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Court analysis</div>
    <a href="../docs/01-stf-reasoning-templates.html">STF Reasoning Templates</a>
    <a href="../docs/02-stj-repetitivos-patterns.html">STJ Repetitivos Patterns</a>
    <a href="../docs/03-tjsp-plans-vs-sus.html">TJSP: Plans vs SUS</a>
    <a href="../docs/04-conitec-pcdt-vs-courts.html">CONITEC vs Courts</a>
    <a href="../docs/05-interfederative-responsibility.html">Interfederative Responsibility</a>
    </div>
  </div>
  <div class="nav-dropdown">
    <button class="nav-link">Data &#9662;</button>
    <div class="dropdown-menu">
    <a href="../sources/tjsp.html">TJSP</a>
    <a href="../sources/datajud.html">DataJud</a>
    <a href="../sources/stf-stj.html">STF & STJ</a>
    <a href="../sources/trf3.html">TRF3</a>
    <a href="../sources/spending.html">Municipal Spending</a>
    <a href="../sources/legislation.html">Health Legislation</a>
    </div>
  </div>
  <a href="../references/index.html" class="nav-link">References</a>
  <a href="../news/index.html" class="nav-link">News</a>
</nav>
<script>
document.querySelectorAll('.nav-dropdown > .nav-link').forEach(function(btn) {
  btn.addEventListener('click', function(e) {
    e.stopPropagation();
    var dd = btn.parentElement;
    var wasOpen = dd.classList.contains('open');
    document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
    if (!wasOpen) dd.classList.add('open');
  });
});
document.addEventListener('click', function() {
  document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
});
</script>

<div class="page-header">
  <h1>Research Q&A</h1>
</div>

<main>
<div class="doc-controls">
  <button id="toggle-sections">Expand all</button>
</div>
<div class="md-body">
<h1>Research Q&amp;A — &quot;Courts, Budgets, and Health&quot;</h1>
<p>Substantive questions for the paper's empirical design, with answers from institutional research (NotebookLM sessions, Feb 2026). Each entry is one question with answer and key takeaways.</p>
<hr />
<h2 id="1-how-does-case-assignment-work-at-tjsp">1. How does case assignment work at TJSP?</h2>
<p><strong>Question.</strong> How does case assignment (distribuição) work at TJSP varas da fazenda pública? Is it automated and random? What are the exceptions (prevenção, conexão, continência)? How many varas da fazenda pública exist in São Paulo capital vs. interior comarcas?</p>
<p><strong>Answer.</strong> Case assignment is conducted through an <strong>automated, random sequential distribution system</strong> designed to ensure balanced workloads and prevent judge-shopping. The mechanism is governed by the CPC and the NSCGJ.</p>
<p>Exceptions:</p>
<ul>
<li><strong>Prevenção:</strong> Related cases (same cause of action or object) are routed to the judge who first presided, to avoid conflicting decisions.</li>
<li><strong>Conexão and continência:</strong> Connected cases are tried together for judicial economy (CPC).</li>
<li><strong>Specialization:</strong> Per CNJ Resolution 238/2016, comarcas with more than one Vara da Fazenda Pública must specialize one vara for public health matters.</li>
</ul>
<p>Distribution: São Paulo Capital accounts for ~23.1% of health cases with at least 16 Varas da Fazenda Pública. The remaining ~76.9% is spread across 313 interior comarcas. There are 1,929 unique judges handling health cases across 314 comarcas. Median caseload ~300 cases, with significant skew.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Random assignment is confirmed — supports Judge IV design.</li>
<li>Key threats to randomness: prevenção (related cases routed to same judge) and specialization (CNJ 238/2016).</li>
<li>77% of cases are in the interior — good for municipal-level analysis since SP capital is excluded from TCE-SP data.</li>
<li>1,929 judges across 314 comarcas — large judge pool for constructing stringency measures.</li>
</ul>
<hr />
<h2 id="2-what-are-grant-rates-and-what-margins-of-judicial-discretion-remain">2. What are grant rates, and what margins of judicial discretion remain?</h2>
<p><strong>Question.</strong> What are typical grant rates for health lawsuits at TJSP? If grant rates are very high, what margins of judicial discretion remain — e.g., granting the exact drug requested vs. a generic substitute, speed of decision, enforcement intensity, partial vs. full grant?</p>
<p><strong>Answer.</strong> Grant rates are consistently high: ~87% overall against municipalities, ~92.9% for medication/treatment-specific requests. First-instance decisions: 74.68% fully granted, 10.39% partially granted. Wang &amp; Ferraz (2013): 85% success rate for preliminary injunctions in SP city. Biehl et al. (2012): plaintiff success generally exceeds 90%.</p>
<p>Margins of discretion:</p>
<ul>
<li><strong>Exact drug vs. generic:</strong> Enunciado 28 directs judges to require technical descriptions rather than brand names, but physicians often prescribe specific brands. Discretion remains.</li>
<li><strong>Partial vs. full grants:</strong> ~10.4% of sentences are only partially granted (limiting duration, requiring periodic medical reports per Enunciado 2).</li>
<li><strong>Enforcement intensity:</strong> Judges can order direct fund seizure (<em>bloqueio/sequestro</em>) from municipal bank accounts. Frequently used when government fails to comply within days.</li>
<li><strong>Speed:</strong> Median decision time for tutela de evidência: 10 days. Substantial judge-level variation.</li>
<li><strong>NAT-Jus consultation:</strong> Since 2016, judges are encouraged to consult NAT-Jus for technical evidence, but many still prioritize the plaintiff's prescription.</li>
</ul>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Grant rate is very high (~87–93%) but not 100%. There is variation to exploit, especially on the intensive margin.</li>
<li>The relevant margin may not be grant/deny. With 10.4% partial grants + variation in enforcement (bloqueio vs. not), speed, and scope (brand vs. generic), the instrument can capture richer variation in judicial stringency.</li>
<li>Multiple stringency measures possible: binary grant, speed of injunction, use of fund seizure, partial vs. full grant.</li>
</ul>
<hr />
<h2 id="3-who-is-the-defendant-and-who-actually-pays">3. Who is the defendant, and who actually pays?</h2>
<p><strong>Question.</strong> When is the municipality the defendant vs. the state vs. the federal government? How does this relate to the SUS pharmaceutical components (CBAF, CESAF, CEAF)? Who actually pays in practice?</p>
<p><strong>Answer.</strong> The defendant is governed by a tension between constitutional <strong>solidary liability</strong> and the administrative <strong>division of competencies</strong>.</p>
<ul>
<li><strong>Tema 793 (STF):</strong> Liability is solidary, but judges must direct fulfillment to the administratively responsible entity.</li>
<li><strong>Tema 1.234:</strong> Non-incorporated drugs ≥210 minimum salaries → Federal Court against the Union; &lt;210 → State Court.</li>
<li><strong>Tema 500:</strong> Unregistered drugs must be filed against the Union.</li>
</ul>
<p>SUS pharmaceutical components map to responsible entities:</p>
<ul>
<li><strong>CBAF (Componente Básico):</strong> Municipality. Basic drugs for primary care.</li>
<li><strong>CESAF (Componente Estratégico):</strong> Union acquires and distributes through states.</li>
<li><strong>CEAF (Componente Especializado):</strong> Group 1A: Union; Group 1B: Union finances, states acquire; Group 2: States; Group 3: Municipality.</li>
</ul>
<p>In practice, <strong>municipalities are the first-line payer</strong> even when not administratively responsible. Under Tema 1.234 (2024), the Union reimburses 65% of costs for non-incorporated drugs when State/Municipality is condemned. For oncology filed before June 2024, the Union reimburses 80%. But pre-2024, municipalities bore full cost.</p>
<p>Judicialized medications consume 8.4% of municipal pharmaceutical budgets on average; over 50% in some cases. Judicial purchases cost 30–44% more than regular SUS procurement [Genicolo-Martins &amp; Furquim de Azevedo 2024].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Municipality is typically the first-line payer — key for our fiscal channel.</li>
<li>Reimbursement mechanisms are recent (Tema 1.234, 2024). Pre-2024 data captures maximum municipal fiscal exposure.</li>
<li>CBAF/CESAF/CEAF structure maps drugs to responsible entity — can classify court-ordered drugs to identify mismatched fiscal burden.</li>
<li>Fund seizure (<em>bloqueio</em>) means judicial orders have immediate, non-negotiable fiscal impact.</li>
</ul>
<hr />
<h2 id="4-can-litigants-choose-their-court-or-judge">4. Can litigants choose their court or judge?</h2>
<p><strong>Question.</strong> Can a health lawsuit plaintiff in São Paulo state choose which vara or comarca to file in? Is there evidence of venue shopping?</p>
<p><strong>Answer.</strong> Plaintiffs <strong>cannot choose a specific vara</strong> — case assignment is automated and random. In districts with multiple Varas da Fazenda Pública, CNJ Resolution 238/2016 mandates specialization of one vara for health.</p>
<p>Territorial competence rules:</p>
<ul>
<li><strong>Against municipality:</strong> Filed in the comarca where the municipality is located (TJSP Súmula 37).</li>
<li><strong>Against state:</strong> CPC allows filing in the state capital or plaintiff's domicile.</li>
<li><strong>Against the Union:</strong> CPC allows filing at plaintiff's domicile.</li>
</ul>
<p>Plaintiffs can generally file in their home comarca. Forum shopping exists on the <strong>entity dimension</strong> (which government to sue), not the <strong>judge dimension</strong>. Tema 793 (2019) partially addresses this. TJSP Súmula 29 prevents defendants from bringing in other government levels mid-case.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>No judge-shopping within a comarca — automated assignment protects random assignment assumption.</li>
<li>Comarca is determined by plaintiff's domicile — supports linking cases to municipalities.</li>
<li>Forum shopping is on the entity dimension (which government to sue), not the judge dimension.</li>
</ul>
<hr />
<h2 id="5-what-is-the-volume-and-geographic-distribution-of-health-cases">5. What is the volume and geographic distribution of health cases?</h2>
<p><strong>Question.</strong> How many health lawsuits are filed per year at TJSP? How are cases distributed geographically? How many of SP's 645 municipalities have significant litigation volume?</p>
<p><strong>Answer.</strong> TJSP handles approximately <strong>325,000 new health cases per year</strong> (~55% private health plans, ~37% SUS, ~120,000 SUS cases/year) [Sintese Tjsp Planos Vs Sus, p. 811].</p>
<p>Trends: New first-instance cases rose from 76,836 (2020) to 162,046 (2024), a 110.9% increase [Ipea 2025, p. 547]. CNJ: public health cases grew 130% from 2008–2017. State-level judicially mandated medication spending reached 32.9% of total state pharmaceutical expenditures by 2023 [Ipea 2025, p. 545].</p>
<p>Geographic distribution: SP Capital ~23.1%, interior ~76.9% across 313 comarcas. Concentration in ABCD region, Campinas, Guarulhos, São José dos Campos. 100% of municipalities &gt;500,000 inhabitants have active health litigation [Ipea 2025, p. 556]. Even among towns &lt;5,000 inhabitants, 36.5% report providing medications due to court orders [Ipea 2025, p. 555].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>~120,000 SUS cases per year at TJSP alone. No power concerns at the aggregate level.</li>
<li>77% interior — aligns well with TCE-SP coverage (644 municipalities, excludes SP capital).</li>
<li>Even small municipalities are affected — wide geographic coverage.</li>
<li>Rapid growth 2008–2024 provides time variation.</li>
</ul>
<hr />
<h2 id="6-what-is-trf3-s-role-and-should-we-include-it">6. What is TRF3's role, and should we include it?</h2>
<p><strong>Question.</strong> How does case assignment work at TRF3? What types of health cases go to TRF3 vs. TJSP? What is TRF3's volume relative to TJSP?</p>
<p><strong>Answer.</strong> TRF3 also uses <strong>automated, random sequential distribution</strong>. CNJ Resolution 238/2016 applies to TRFs as well. Jurisdiction split:</p>
<ul>
<li>TJSP: Cases against the State of São Paulo or a Municipality. Most SUS demands.</li>
<li>TRF3: Cases against the Federal Government (União) or INSS.</li>
<li>Tema 1.234: Non-incorporated drugs ≥210 minimum salaries → Federal Court.</li>
<li>Tema 500: Unregistered drugs → Federal Court.</li>
</ul>
<p>TJSP volume is significantly higher. TJSP accounted for 48.82% (80,355 cases) of national health acórdãos (2008–2017), while TRF3's share was much smaller. However, federal cases tend to be the most expensive — the Union spent R$1.9 billion on judicial medication orders in 2024 [Ipea 2025, p. 549].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>TRF3 has random assignment — could serve as a robustness sample.</li>
<li>Volume is much smaller — likely not enough for standalone analysis.</li>
<li>TRF3 cases are higher-cost (Union as defendant, expensive drugs) — different margin than TJSP municipal cases.</li>
<li><strong>For the main analysis, TJSP is the right court.</strong> TRF3 is a possible extension.</li>
</ul>
<hr />
<h2 id="7-how-did-the-2018-stj-ruling-tema-106-and-other-jurisprudential-shifts-affect-litigation">7. How did the 2018 STJ ruling (Tema 106) and other jurisprudential shifts affect litigation?</h2>
<p><strong>Question.</strong> What were the specific Tema 106 criteria? Did grant rates decline for off-list drugs? What other major jurisprudential shifts changed health litigation patterns?</p>
<p><strong>Answer.</strong> Tema 106 criteria (cumulative, from May 4, 2018): (1) Detailed medical report proving necessity and that SUS drugs are ineffective; (2) Evidence of plaintiff's financial inability to afford treatment; (3) Medication must be registered with ANVISA.</p>
<p>Impact was minimal: fewer than 6% of cases cite technical standards (CONITEC, RENAME) in decisions [CNJ/Insper 2019]. &quot;Supply of medicines&quot; cases showed only a 4% dip between 2017–2018. Grant rates remain ~92.9% at TJSP for medication requests against municipalities. Overall litigation continued to accelerate post-2020.</p>
<p>Other major shifts:</p>
<ul>
<li><strong>Tema 500 (2019):</strong> State cannot be forced to provide medications without ANVISA registration.</li>
<li><strong>Tema 793 (2019):</strong> Solidary liability clarified; judges must direct to the administratively responsible entity.</li>
<li><strong>Tema 1.234 &amp; Tema 6 (2024):</strong> Consolidated criteria for non-incorporated drugs. ≥210 minimum salaries → Federal Court. Union reimburses 65%.</li>
<li><strong>Súmulas Vinculantes 60 and 61 (2024):</strong> Mandate interfederative agreements and administrative exhaustion requirement.</li>
</ul>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Tema 106 had minimal impact on grant rates — judges still grant ~93%. The criteria exist on paper but are weakly enforced.</li>
<li>Timeline of jurisprudential shocks: 2018 (Tema 106), 2019 (Tema 500, 793), 2024 (Tema 1.234, SV 60/61) — provides natural experiment variation.</li>
<li>6% citation rate for technical standards highlights judge-level heterogeneity in stringency.</li>
</ul>
<hr />
<h2 id="8-how-well-does-siops-capture-the-crowd-out-channel">8. How well does SIOPS capture the crowd-out channel?</h2>
<p><strong>Question.</strong> What expenditure categories are available in SIOPS at the municipal level? Can we separately observe primary care, hospital, pharmaceutical, and surveillance spending? Is there a line item for judicially mandated spending?</p>
<p><strong>Answer.</strong> SIOPS expenditure categories follow Portaria 42/1999 subfunções within Função 10 (Saúde):</p>
<ul>
<li><strong>301 — Atenção Básica:</strong> ESF, community health agents, UBS. Preventive care.</li>
<li><strong>302 — Assistência Hospitalar e Ambulatorial:</strong> Hospitals, emergency rooms, clinics.</li>
<li><strong>303 — Suporte Profilático e Terapêutico:</strong> Pharmaceutical assistance, blood banks, vaccines, devices.</li>
<li><strong>304 — Vigilância Sanitária:</strong> Product/environment inspection.</li>
<li><strong>305 — Vigilância Epidemiológica:</strong> Disease notification, outbreak investigation.</li>
<li><strong>306 — Alimentação e Nutrição:</strong> Nutritional surveillance.</li>
</ul>
<p>Categories have been consistent since 1999. Assistência Farmacêutica is not a standalone subfunção — it is embedded within 303. SIOPS <strong>does not have a specific line item for judicially mandated spending</strong>. Court-ordered expenditures are mixed into other categories, typically 303 and 302.</p>
<p>Data quality: reporting is mandatory (suspension of transfers for non-compliance), but breakdown by category is often unreliable. Significant inconsistency in how municipalities assign expenses to subfunção 301. SIOPS relies on self-reported aggregates — less granular than TCE-SP.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>SIOPS confirms the subfunção structure for crowd-out analysis: 301 (primary care, the victim) vs. 303 (pharmaceutical/therapeutic, the destination of judicial spending).</li>
<li>SIOPS cannot identify judicial spending directly — reinforces the value of TCE-SP with its <code>historico_despesa</code> tagging.</li>
<li>TCE-SP is the primary spending measure; SIOPS serves as a robustness check (universal coverage, long time series).</li>
</ul>
<hr />
<h2 id="9-how-do-municipalities-comply-with-court-orders-and-how-quickly">9. How do municipalities comply with court orders, and how quickly?</h2>
<p><strong>Question.</strong> What is the typical timeline from a preliminary injunction to actual delivery? What happens when a municipality fails to comply? How often do municipalities resist?</p>
<p><strong>Answer.</strong> Only 50–60% of municipal health secretariats have dedicated units to handle judicial orders [CNJ 2021, p. 270]. Compliance often involves direct purchase from municipal funds, even for treatments that are the responsibility of other government levels [Fiocruz 2020, p. 463].</p>
<p>Timelines: Median time to grant a preliminary injunction at TJSP: 10 days [Tutela Provisoria Senado, p. 1443]. National average filing to final judgment: 432 days [Stf Temas Desafios Academico, p. 888]. Actual delivery can take six months or more despite a court order [CNJ/Insper 2019, p. 202].</p>
<p>Enforcement tools: (1) <em>Bloqueio/sequestro de verbas</em>: direct seizure from municipal bank account, established under STJ Tema 84. (2) <em>Multa diária</em> (astreintes): daily fines, validated by STJ Tema 98. (3) <em>Responsabilização pessoal</em>: personal liability for public officials under Penal Code Art. 330.</p>
<p>Fund seizures are described by managers as &quot;catastrophic&quot; for fiscal planning [CNJ/Insper 2019, p. 202]. Small municipalities under solidary liability are ordered to pay for high-complexity treatments they do not operate [Fiocruz 2020, p. 463]. 52.1% of municipalities have established &quot;administrative paths&quot; to provide non-incorporated medications extrajudicially, preventing lawsuits [Ipea 2025, p. 545].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Fast judicial action, slow administrative compliance: 10-day median to injunction vs. months for actual delivery. Important for timing the first-stage spending shock.</li>
<li>Enforcement is credible and severe: fund seizures and daily fines make non-compliance very costly.</li>
<li>Municipalities bear the burden despite mismatched responsibility.</li>
<li>Administrative paths as endogenous response: 52.1% now offer extrajudicial provision — could attenuate the litigation-spending relationship over time.</li>
</ul>
<hr />
<h2 id="10-how-do-municipalities-procure-judicially-mandated-medicines">10. How do municipalities procure judicially mandated medicines?</h2>
<p><strong>Question.</strong> Do municipalities use emergency purchases? How are prices determined? What explains the 30–44% cost premium?</p>
<p><strong>Answer.</strong> Municipalities rely on emergency purchases (<em>dispensa de licitação</em>) or direct contracting because court orders mandate compliance within 24 hours to 15 days [Ipea 2025, p. 557]. Standard bidding is too slow. Judges sometimes grant direct access to municipal accounts for fund seizures, allowing the plaintiff to purchase at a commercial pharmacy [CNJ/Insper 2019, p. 200].</p>
<p>STF Tema 1.234 sets a price ceiling at the PMVG (Preço Máximo de Venda ao Governo), but this is new (2024) and doesn't apply to our sample period. In practice, when judges order fund seizures, drugs are bought at private pharmacies at market prices.</p>
<p>The 30–44% cost premium [Genicolo-Martins &amp; Furquim de Azevedo 2024] is explained by: (1) retail buying — small quantities at higher unit costs; (2) strategic industry behavior — pharmaceutical companies reportedly delay registration or SUS incorporation to profit from higher non-negotiated judicial-channel prices [Ipea 2025, p. 577]; (3) brand specificity — courts mandate specific brands rather than generics, preventing competitive substitution.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Procurement inefficiency is structural: emergency/retail purchases mechanically inflate costs. Key amplifier of the crowd-out mechanism.</li>
<li>Pre-2024 purchases had no effective price constraint — our sample period captures maximum cost premium.</li>
<li>Pharma industry incentives are perverse: deliberate delay of SUS incorporation to profit from the judicial channel.</li>
<li>Each judicial real displaces more than one real of planned spending due to the cost premium.</li>
</ul>
<hr />
<h2 id="11-do-appeals-actually-reverse-the-fiscal-impact">11. Do appeals actually reverse the fiscal impact?</h2>
<p><strong>Question.</strong> What fraction of cases are appealed? What is the reversal rate? Since most orders are enforced via preliminary injunction, does the appeal outcome actually matter fiscally?</p>
<p><strong>Answer.</strong> States and municipalities are the primary appellants, often as an administrative duty. Approximately 55% of first-instance health cases (277,411 of 498,715) reached the second instance nationally (2008–2017) [CNJ/Insper 2019, p. 87]. First-instance grant rate against municipalities: 87.8% overall, 92.9% for medication requests.</p>
<p>Reversals on appeal are difficult: many cases are rendered moot because the obligation has been fulfilled via preliminary injunction [CNJ/Insper 2019, p. 84]. Technically, plaintiffs are liable for damages if an injunction is reversed, but treatments are treated as &quot;irrepetíveis&quot; (non-returnable) once consumed, especially for financially incapacitated patients. Average case duration at TJSP: ~21 months. The fiscal impact occurs at the preliminary stage and persists regardless of appellate outcome.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>First-instance decisions are what matter fiscally: preliminary injunctions are enforced immediately (10-day median), and reversals almost never recover funds.</li>
<li>This validates using first-instance outcomes (not final appellate outcomes) for instrument construction.</li>
<li>~21 month average case duration is useful for calibrating the timing window between litigation shock and health outcome measurement.</li>
</ul>
<hr />
<h2 id="12-who-litigates-defensoria-p-blica-private-attorneys-or-minist-rio-p-blico">12. Who litigates — Defensoria Pública, private attorneys, or Ministério Público?</h2>
<p><strong>Question.</strong> What fraction of cases go through each channel? Do cases differ systematically? Is there geographic variation in Defensoria coverage? Are there organized litigation networks?</p>
<p><strong>Answer.</strong> Private attorneys represent the vast majority: ~55% of TJSP annual health volume is health plan litigation dominated by private attorneys. Defensoria Pública handles ~6.91% of first-instance sentencing volume; nationally only ~20% of health litigants are economically vulnerable [CNJ 2021, p. 269]. Ministério Público handles 3.11%, primarily through collective actions.</p>
<p>Defensoria eligibility: family income up to 3 minimum salaries in SP. Defensoria coverage is concentrated in urban hubs; interior coverage is a major challenge. Programs like Acessa SUS are restricted to capital/metropolitan areas.</p>
<p>Organized networks: 6 lawyers responsible for 35% of all health cases against the state in a single year; a single physician wrote 66% of prescriptions for a specific judicialized drug [TCU]. Companies reportedly delay ANVISA registration because judicial purchases are 30–44% more expensive than bulk SUS procurement [Ipea 2025, p. 577].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Private attorneys dominate, not Defensoria: only ~7% of first-instance cases. Challenges the narrative that litigation serves the poor.</li>
<li>Health plan vs. SUS distinction is essential: ~55% of TJSP health cases are private health plans, not SUS. Must filter carefully.</li>
<li>Concentration of litigation actors suggests organized, possibly pharma-driven networks.</li>
<li>Interior litigants are likely even more skewed toward those who can afford private representation, since Defensoria coverage is thin outside urban hubs.</li>
</ul>
<hr />
<h2 id="13-what-is-the-primary-care-infrastructure-across-sp-municipalities">13. What is the primary care infrastructure across SP municipalities?</h2>
<p><strong>Question.</strong> What is ESF coverage variation between capital and interior? How are municipal primary care budgets allocated across subfunções?</p>
<p><strong>Answer.</strong> Each ESF team (physician, nurse, nursing technicians, community health agents) covers 3,000–4,000 people. National coverage expanded from 4% in 1998 to over 60% by mid-2010s. Access to primary care is higher in the South/Southeast including SP.</p>
<p>Budget allocation by subfunção (from TCE-SP 2022 sample):</p>
<ul>
<li>Subfunção 301 (Atenção Básica): ESF, community health agents, traditional UBS. Largest by transaction volume (~68,000 records in 2022).</li>
<li>Subfunção 302 (Assistência Hospitalar e Ambulatorial): hospitals, clinics. ~3,892 records in 2022.</li>
<li>Subfunção 303 (Suporte Profilático e Terapêutico): pharmaceutical assistance, devices. Where judicially mandated drug purchases concentrate.</li>
<li>Subfunção 122 (Administração Geral): significant spending due to <em>matricialidade</em> — captures administrative overhead.</li>
</ul>
<p>In specific SP municipalities, judicial spending reached 6.8% of total health budget (Bariri) and 6.2% (Bento de Abreu) in 2022. In 2023, judicially mandated medications averaged 8.4% of total municipal pharmaceutical budgets [Ipea 2025, p. 545].</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Subfunção 301 dominates transaction volume — this is what's at risk of crowd-out when 303 is inflated by court orders.</li>
<li>Subfunção 122 noise: significant spending under Administração Geral due to matricialidade. Need to either exclude or investigate.</li>
<li>Record counts don't equal spending shares: primary care has many small transactions; hospital spending has fewer but larger ones.</li>
</ul>
<hr />
<h2 id="14-how-feasible-is-linking-litigants-to-cad-nico-and-rais">14. How feasible is linking litigants to CadÚnico and RAIS?</h2>
<p><strong>Question.</strong> How complete is CadÚnico for identifying low-income individuals in SP? What fraction of the working-age population appears in RAIS? How feasible is name-based linkage between court records and these datasets?</p>
<p><strong>Answer.</strong> CadÚnico enrollment criterion: per capita income up to half the minimum wage. Only ~20% of health litigants are identified as economically vulnerable (via CadÚnico enrollment or public defender representation) [CNJ 2021, p. 269]. RAIS is an annual census of all formal-sector employment relationships; records wages, occupation, employer.</p>
<p>Name-based linkage is feasible because full name combinations in Brazil are often unique. Challenges: common names (false positives), transcription errors, varied spelling. The CNJ/Insper study used the Jaro distance algorithm for fuzzy name matching in court records [CNJ/Insper 2019, p. 84, 130]. Wang &amp; Ferraz (2013) examined litigant profiles in SP using similar approaches.</p>
<p><strong>Key takeaways.</strong></p>
<ul>
<li>Jaro distance for name matching is established in the judicial context — provides precedent.</li>
<li>20% economically vulnerable is the key equity number: CadÚnico linkage will characterize a minority of litigants, while RAIS will capture the formally employed majority.</li>
<li>Coverage statistics for SP specifically need to come from IBGE/MDS documentation and the economics literature on Brazilian administrative data linkage (e.g., Gerard et al. 2021 on RAIS).</li>
</ul>

</div>
</main>

<footer>
  Generated by <code>bash build.sh site</code>
</footer>

<script>
document.addEventListener('DOMContentLoaded', () => {
  const body = document.querySelector('.md-body');
  if (!body) return;

  function foldHeadings(container, tag) {
    const level = tag.replace('H', '');
    const headings = Array.from(container.querySelectorAll(':scope > ' + tag.toLowerCase()));
    headings.forEach(h => {
      const details = document.createElement('details');
      details.className = 'level-' + level;
      if (h.id) details.id = h.id;
      const summary = document.createElement('summary');
      summary.innerHTML = h.innerHTML;
      details.appendChild(summary);
      let sibling = h.nextElementSibling;
      const collected = [];
      while (sibling && sibling.tagName !== tag) {
        collected.push(sibling);
        sibling = sibling.nextElementSibling;
      }
      collected.forEach(el => details.appendChild(el));
      h.replaceWith(details);
    });
    return headings.length;
  }

  // Fold h2 sections, then h3 sections within each h2
  const count = foldHeadings(body, 'H2');
  if (count === 0) {
    document.querySelector('.doc-controls').style.display = 'none';
    return;
  }
  body.querySelectorAll('details.level-2').forEach(d => foldHeadings(d, 'H3'));

  // Toggle button
  const btn = document.getElementById('toggle-sections');
  if (!btn) return;
  btn.addEventListener('click', () => {
    const allDetails = body.querySelectorAll('details');
    const expanding = btn.textContent === 'Expand all';
    allDetails.forEach(d => d.open = expanding);
    btn.textContent = expanding ? 'Collapse all' : 'Expand all';
  });

  // Auto-open details when navigating to an anchor
  function openAnchorTarget() {
    if (!location.hash) return;
    const target = document.querySelector(location.hash);
    if (!target) return;
    let el = target;
    while (el) {
      if (el.tagName === 'DETAILS') el.open = true;
      el = el.parentElement;
    }
    target.scrollIntoView();
  }
  openAnchorTarget();
  window.addEventListener('hashchange', openAnchorTarget);
});
</script>

</body>
</html>
